Mehrdad Rakaee

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity.

DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity.

Journal: bioRxiv : the preprint server for biology
Published: July 11, 2026

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction-Reply.

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction-Reply.

Journal: JAMA oncology
Published: May 14, 2026

Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.

Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.

Journal: JAMA oncology
Published: February 12, 2026

Cell-Targeted Inhibition of CaMK4 Suppresses Tertiary Lymphoid-like Structure Development in Lupus-Prone Mice.

Cell-Targeted Inhibition of CaMK4 Suppresses Tertiary Lymphoid-like Structure Development in Lupus-Prone Mice.

Journal: International journal of molecular sciences
Published: February 05, 2026

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 17, 2025

Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study.

Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study.

Journal: JTO clinical and research reports
Published: September 09, 2025

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal: Journal of hepatology
Published: September 04, 2025

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Journal for immunotherapy of cancer
Published: August 31, 2025

CD3+RUNX3+ lymphocyte density; an independent prognostic factor in colon and lung adenocarcinoma but not in lung squamous cell carcinoma.

CD3+RUNX3+ lymphocyte density; an independent prognostic factor in colon and lung adenocarcinoma but not in lung squamous cell carcinoma.

Journal: Scientific reports
Published: August 14, 2025

Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.

Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.

Journal: Journal of the National Cancer Institute
Published: July 07, 2025

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.

Journal: Nature communications
Published: May 11, 2025

Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status.

Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status.

Journal: Frontiers in oncology
Published: April 06, 2025
Showing 1-12 of 40

Last Updated: 09/26/2026